Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 5:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Control powder Clear all
Completed Phase 2 Interventional Results available

A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy

NCT01645280
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Placebo + methotrexate (MTX) (Group 1), Ustekinumab + MTX (Group 2), Ustekinumab + MTX (Group 3), CNTO 1959 + MTX (Group 4), CNTO 1959 + MTX (Group 5)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Palm Harbor, Florida • Rock Island, Illinois • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation

NCT04456673
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 85 Years
Enrollment
935 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
92
States / cities
Cullman, Alabama • Jasper, Alabama • Scottsboro, Alabama + 79 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of the Inno Cleanse Dietary Supplement on Gut Health and Associated Variables in Healthy Men and Women

NCT07215351
View directory record Official record
Conditions
Constipation, Bloating
Interventions
Dietary supplement for digestive health, placebo capsule
Dietary Supplement
Lead sponsor
University of Memphis
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

NCT02836496
View directory record Official record
Conditions
Hypereosinophilic Syndrome
Interventions
Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg prednisolone or prednisone), Placebo matching OCS capsules
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
San Diego, California • New Haven, Connecticut • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Sep 8, 2026, 5:31 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms

NCT03421496
View directory record Official record
Conditions
Infantile Spasm
Interventions
Cannabidiol Oral Solution, Placebo, Vigabatrin
Drug
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
1 Month to 24 Months
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Miami, Florida • Royal Oak, Michigan • Akron, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Sep 8, 2026, 5:31 PM EDT
Recruiting Phase 3 Interventional

A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma

NCT06664619
View directory record Official record
Conditions
Asthma
Interventions
Fp/ABS, FP, ABS, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
12 Years and older
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
91
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 73 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Phase 2 Interventional

Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV

NCT00863239
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
ribavirin, Locteron™ (controlled-release interferon alpha 2b), PEG-Intron™
Drug
Lead sponsor
Biolex Therapeutics, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
13
States / cities
Chula Vista, California • Oceanside, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Phase 4 Interventional Results available

Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.

NCT01966107
View directory record Official record
Conditions
COPD, Chronic Obstructive Pulmonary Disease, Moderate to Very Severe COPD
Interventions
Aclidinium Bromide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
3,635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
433
States / cities
Birmingham, Alabama • Florence, Alabama • Foley, Alabama + 334 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Not applicable Interventional

Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy

NCT01049399
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
tideglusib, placebo
Drug
Lead sponsor
Noscira SA
Industry
Eligibility
40 Years to 85 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
6
States / cities
Fountain Valley, California • Los Angeles, California • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2012 · Synced Sep 8, 2026, 5:31 PM EDT
Recruiting Phase 4 Interventional

Depo-Medrol on Psoas After LLIF

NCT05929755
View directory record Official record
Conditions
Muscle Weakness, Pain, Postoperative, Paresthesia, Pain, Muscle
Interventions
Depo-Medrol, Gel-Flow NT
Drug
Lead sponsor
Hardeep Singh
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Randomized Controlled Cocoa-Appetite Trial

NCT02408289
View directory record Official record
Conditions
Obesity
Interventions
Lo-Flav, Hi-Flav, Epicatechin, Procyanidins
Dietary Supplement
Lead sponsor
Brooklyn College of the City University of New York
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Acid-Base Compensation in Chronic Kidney Disease

NCT02427594
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Sodium bicarbonate, Controlled diet
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
22 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Study to Evaluate the Effect of Naturlose (Tagatose)

NCT00961662
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
D-Tagatose
Drug
Lead sponsor
Robert Lodder
Industry
Eligibility
18 Years to 75 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Garden Grove, California • Miami, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of PF-05175157 in Healthy Volunteers and Type 2 Diabetic Patients

NCT01396161
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-05175157 or Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
3
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 6, 2016 · Synced Sep 8, 2026, 5:31 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Nutritional Supplementation in the Elderly With Weight Loss

NCT04350762
View directory record Official record
Conditions
Sarcopenia
Interventions
Protein shake + Fish Oil
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
65 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness

NCT03137992
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Placebo, Test Product (tiotropium bromide inhalation powder), Reference Product (Spiriva®)
Drug
Lead sponsor
Lupin, Inc.
Industry
Eligibility
40 Years and older
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
34
States / cities
Andalusia, Alabama • Jasper, Alabama • Glendale, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2021 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants

NCT01180790
View directory record Official record
Conditions
Hepatitis C
Interventions
ACH-0141625 (Sovaprevir), Placebo, Pegylated Interferon alpha-2a, Ribavirin
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Bradenton, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)

NCT01089127
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
69
States / cities
Florence, Alabama • Jasper, Alabama • Phoenix, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

NCT00787761
View directory record Official record
Conditions
Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2012 · Synced Sep 8, 2026, 5:31 PM EDT
Active, not recruiting Not applicable Interventional

Myo-Inositol for Infertility in PCOS

NCT04407754
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Inositol supplement, Placebo supplement
Dietary Supplement
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 36 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal Burns

NCT02148705
View directory record Official record
Conditions
Thermal Burns
Interventions
NexoBrid, Standard of Care (SOC), Gel Vehicle
Drug · Procedure
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years to 77 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
18
States / cities
Mobile, Alabama • Phoenix, Arizona • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Repeated Dose Escalation Study of GSK2838232

NCT02795754
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2838232 PIB, GSK2838232 IR1, GSK2838232 IR2, Placebo PIB, Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Phase 1 Interventional Results available

A Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Doses Of PF-04937319 In Subjects With Type 2 Diabetes Mellitus

NCT01044537
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Placebo, PF-04937319
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Phoenix, Arizona • Cypress, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01154127
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
NVA237, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2012 · Synced Sep 8, 2026, 5:31 PM EDT